NCT03341871View on ClinicalTrials.gov

Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6

CompletedOBSERVATIONAL
Enrollment

1,095

Participants

Timeline

Start Date

December 27, 2017

Primary Completion Date

September 15, 2020

Study Completion Date

September 15, 2020

Conditions
Hepatitis C Virus (HCV)
Trial Locations (1)

108-6302

Abbvie Japan /ID# 161985, Tokyo

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY